ID   GEN2.2
AC   CVCL_5G44
SY   Gen2.2; GEN 2.2; Gen 2.2; HLA-A*0201+ pDC line
DR   Wikidata; Q54835560
RX   Patent=US7341870;
RX   PubMed=16365416;
RX   PubMed=22696054;
WW   https://web.archive.org/web/20160706131224/http://www.clg.niigata-u.ac.jp:80/~matak/eng/resmat12.pdf
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-2938.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: Plasmacytoid dendritic cell; CL=CL_0000784.
DI   NCIt; C7203; Blastic plasmacytoid dendritic cell neoplasm
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_5G45 ! GEN3
SX   Male
AG   74Y
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 29-06-23; Version: 8
//
RX   Patent=US7341870;
RA   Plumas J., Chaperot L.;
RT   "Dendritic cell line.";
RL   Patent number US7341870, 11-Mar-2008.
//
RX   PubMed=16365416; DOI=10.4049/jimmunol.176.1.248;
RA   Chaperot L., Blum A., Manches O., Lui G., Angel J., Molens J.-P.,
RA   Plumas J.;
RT   "Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of
RT   plasmacytoid dendritic cells.";
RL   J. Immunol. 176:248-255(2006).
//
RX   PubMed=22696054; DOI=10.1038/jid.2012.152;
RA   Aspord C., Leccia M.-T., Salameire D., Laurin D., Chaperot L.,
RA   Charles J., Plumas J.;
RT   "HLA-A(*)0201(+) plasmacytoid dendritic cells provide a cell-based
RT   immunotherapy for melanoma patients.";
RL   J. Invest. Dermatol. 132:2395-2406(2012).
//